-- 尽管投资者因担忧美伊冲突升级而采取避险策略,阿联酋股市在周五最后一个交易日仍收涨。 周五收盘时,富时ADX综合指数上涨0.110%,而迪拜金融市场综合指数涨幅略显平淡,仅上涨0.014%。 多家媒体报道称,伊朗威胁称,如果美国决定再次发动袭击,伊朗将打击美国阵地。受此消息影响,油价周五上涨。此前,Axios的一篇报道指出,美国总统特朗普将听取有关针对伊朗采取新军事行动的简报。 “我们即将迎来又一个充满不确定性的周末。许多人认为,5月1日星期五是美伊两国就某种协议达成协议的关键一天。然而,目前各方对此的希望正在逐渐渺茫,这可能导致局势再次朝着武力冲突的方向发展。这对市场来说并非好事,市场更希望尽快重新开放海峡,即便最终达成的协议并不理想。”荷兰国际集团(ING)表示。 截至阿联酋时间下午3点21分,布伦特原油期货价格接近每桶110.89美元,较前一日上涨0.44%。 与此同时,阿联酋中央银行推出了一项服务,允许非居民游客使用其旅游身份开设数字银行账户。该服务由阿联酋中央银行与联邦身份、公民、海关和港口安全局以及阿布扎比商业银行(ADX:ADCB)合作推出。 企业方面,Pure Health(ADX:PUREHEALTH)公布第一季度归属于母公司股东的利润有所下降。这家在阿布扎比上市的医疗保健服务公司股价收盘上涨0.47%。 另一方面,迪拜金融市场(DFM:DFM)同期归属于母公司股东的利润跃升至1.777亿阿联酋迪拉姆,这得益于其营收同比增长36%。该交易所运营商的股价收盘上涨0.70%。 展望下周,当地经济将迎来4月份的标普全球采购经理人指数(PMI)报告。该指数3月份跌至52.9。
Related Articles
Research Alert: CFRA Retains Hold View On Shares Of Incyte Corporation
CFRA, an independent research provider, has providedwith the following research alert. Analysts at CFRA have summarized their opinion as follows:After Q1 earnings, we keep our target at $102, 11.8x our projected 2027 EPS forecast, below its five-year historical forward P/E average of 17.0x. We adjust our 2026 EPS estimate to $7.83 from $7.94 and our 2027 EPS view to $8.64 from $8.36. INCY reported a solid start to 2026, beating expectations on both revenue and earnings, led by robust, double-digit growth across its commercial portfolio. We think the company is going through a strategic transition beyond its cornerstone product, Jakafi, toward a diversified portfolio in hematology, oncology, and immunology, supported by a maturing late-stage pipeline and key management appointments. INCY announced the appointments of Suketu Upadhyay (the current CFO of ZBH) as its new CFO, effective May 4, and a new Head of U.S. Commercial, Mohamed Issa. While we see some execution risks ahead, we believe INCY could be at an inflection point with four new product launches in the next year and the advancement of the 10 Phase 3 studies while filling key leadership roles.
ISM US Manufacturing Index Indicates Steady Expansion in April
The Institute for Supply Management's US manufacturing index was unchanged in April from the 52.7 reading in March, below the expectations for a 53.2 reading in a survey compiled by Bloomberg as of 7:40 am ET.There were gains in the readings for new orders and prices, but declines in production, employment and order backlogs.Other regional manufacturing sector readings have been generally positive, with exception of the Dallas and Chicago regions.The monthly national manufacturing reading from the Institute for Supply Management is reported as a headline index, with readings above 50 indicating expansion and those below 50 indicating contraction. Component indexes measure new orders, production, employment, and prices.An increase in the index further above 50 is considered a sign of a strong US manufacturing sector, generally a positive for manufacturing industry stocks. However, if that strength comes with rising input prices due to shortages, that could be a negative for stocks as well as bonds.
B. Riley Initiates Unicycive Therapeutics at Buy With $22 Price Target
Unicycive Therapeutics (UNCY) has an average rating of buy and mean price target of $41.33, according to analysts polled by FactSet.(covers equity, commodity and economic research from major banks and research firms in North America, Asia and Europe. Research providers may contact us here: https://www..com/contact-us)Price: $7.62, Change: $-0.04, Percent Change: -0.59%